Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xevinapant with chemoradiotherapy in locally advanced head and neck cancer
NCT04459715Phase 3Terminated
- Sponsor
- EMD Serono
- Start
- Aug 2020
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 26
01
Overview
A Phase 3 trial of xevinapant in squamous cell carcinoma of the head and neck (HNSCC), sponsored by EMD Serono. Started Aug 2020; status: terminated.
02
Drugs
xevinapant
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT04459715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04459715.